Cedar Fair LP
Change company Symbol lookup
Select an option...
FUN Cedar Fair LP
BAC Bank of America Corp
XLF Financial Select Sector SPDR® Fund
FRAN Francesca's Holdings Corp
ED Consolidated Edison Inc
BIIB Biogen Inc
CNF CNFinance Holdings Ltd
LVS Las Vegas Sands Corp
AZDDQ Azure Dynamics Corp
$DWACSMN Dorsey Wright Country Stock NTRIndex
Go

Consumer Discretionary : Hotels, Restaurants & Leisure | Small Cap Blend
Company profile

Cedar Fair, L.P. is an operator of regional amusement parks. The Company operates within a segment of amusement/water parks with accompanying resort facilities. As of December 31, 2016, the Company owned approximately 11 amusement parks, two separately gated outdoor water parks, one indoor water park and five hotels. The amusement parks include Cedar Point, located on Lake Erie between Cleveland and Toledo in Sandusky, Ohio; Knott's Berry Farm, near Los Angeles, California; Canada's Wonderland, near Toronto, Canada; Kings Island, near Cincinnati, Ohio; Carowinds, in Charlotte, North Carolina; Dorney Park & Wildwater Kingdom (Dorney Park), in Allentown, Pennsylvania; Kings Dominion, near Richmond, Virginia; California's Great America, in Santa Clara, California; Valleyfair, near Minneapolis/St. Paul, Minnesota; Worlds of Fun, in Kansas City, Missouri, and Michigan's Adventure, in Muskegon, Michigan. It manages and operates Gilroy Gardens Family Theme Park in Gilroy, California.

Closing Price
$28.26
Day's Change
0.07 (0.25%)
Bid
--
Ask
--
B/A Size
--
Day's High
29.90
Day's Low
28.13
Volume
(Below Average)
Volume:
591,624

10-day average volume:
718,399
591,624

Vaxart: Emergent to manufacture Vaxart's experimental COVID-19 vaccine

7:54 am ET March 18, 2020 (MarketWatch)
Print

Shares of Vaxart Inc. (VXRT) jumped 48% in premarket trading on Wednesday after the company said it had signed a deal with Emergent BioSolutions Inc. (EBS) to help develop and manufacture Vaxart's COVID-19 oral vaccine candidate. Emergent's stock was up 4% before the market opened. "We believe an oral vaccine administered using a room temperature-stable tablet may offer enormous logistical advantages in the roll-out of a large vaccination campaign," Vaxart CEO Wouter Latour said in a news release. The company, which had first announced plans to develop a vaccine on Jan. 31, expects to start a Phase 1 clinical trial in the second half of the year. Emergent is also contracting with Novavax Inc. (NVAX) on its vaccine candidate, and it has said it is developing two products to prevent or treat COVID-19 infections. Year-to-date, Emergent's stock is up 6.8%, while Vaxart is up 450.6%. The S&P 500 is down 21.7%.

-Jaimy Lee; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

March 18, 2020 07:54 ET (11:54 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.